News
HBPCF
1.730
NaN%
--
Helix Biopharma GAAP EPS of -$0.05
Seeking Alpha · 03/17 19:49
Helix BioPharma Corp. GAAP EPS of C$-0.01
Seeking Alpha · 03/17 16:06
Helix Biopharma GAAP EPS of -$0.09
Seeking Alpha · 10/29/2025 21:49
Weekly Report: what happened at HBPCF last week (0908-0912)?
Weekly Report · 09/15/2025 11:06
Weekly Report: what happened at HBPCF last week (0901-0905)?
Weekly Report · 09/08/2025 11:08
Weekly Report: what happened at HBPCF last week (0825-0829)?
Weekly Report · 09/01/2025 11:03
Weekly Report: what happened at HBPCF last week (0818-0822)?
Weekly Report · 08/25/2025 11:14
Weekly Report: what happened at HBPCF last week (0811-0815)?
Weekly Report · 08/18/2025 11:06
Weekly Report: what happened at HBPCF last week (0804-0808)?
Weekly Report · 08/11/2025 11:13
Weekly Report: what happened at HBPCF last week (0728-0801)?
Weekly Report · 08/04/2025 11:15
Weekly Report: what happened at HBPCF last week (0721-0725)?
Weekly Report · 07/28/2025 11:16
Weekly Report: what happened at HBPCF last week (0714-0718)?
Weekly Report · 07/21/2025 11:06
Weekly Report: what happened at HBPCF last week (0707-0711)?
Weekly Report · 07/14/2025 11:15
Weekly Report: what happened at HBPCF last week (0630-0704)?
Weekly Report · 07/07/2025 11:07
Weekly Report: what happened at HBPCF last week (0623-0627)?
Weekly Report · 06/30/2025 11:13
Weekly Report: what happened at HBPCF last week (0616-0620)?
Weekly Report · 06/23/2025 11:06
Weekly Report: what happened at HBPCF last week (0609-0613)?
Weekly Report · 06/16/2025 11:13
Weekly Report: what happened at HBPCF last week (0602-0606)?
Weekly Report · 06/09/2025 11:14
Weekly Report: what happened at HBPCF last week (0526-0530)?
Weekly Report · 06/02/2025 11:23
Weekly Report: what happened at HBPCF last week (0519-0523)?
Weekly Report · 05/26/2025 11:22
More
Webull provides a variety of real-time HBPCF stock news. You can receive the latest news about Helix Biopharma through multiple platforms. This information may help you make smarter investment decisions.
About HBPCF
Helix BioPharma Corp. is a clinical-stage biopharmaceutical company developing therapies in the field of immuno-oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47. The Company’s pipeline is led by Tumor Defense Breaker L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with the Company's next-generation bi-specific antibody-drug conjugates (ADCs), in discovery. The Company is also advancing two pre-IND candidates: LEUMUNA, an oral immune checkpoint modulator aimed at achieving durable remission in post-transplant leukemia relapse, and GEMCEDA, an oral gemcitabine prodrug with bioavailability on a par with IV, designed to expand treatment options for advanced cancers.